This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medical Action Industries Reports Fourth Quarter And Fiscal 2012 Results

Medical Action Industries Inc. (the “Company” or “Medical Action”) (NASDAQ/MDCI), a leading supplier of medical and surgical disposable products, today reported results for the fourth quarter and fiscal year ended March 31, 2012.

Net sales for the fourth quarter of fiscal 2012 were $108.2 million, an increase of $3.0 million or 3%, compared to $105.3 million in net sales reported for the comparable prior year period. The Company incurred a net loss for the fourth quarter of fiscal 2012 of $2.5 million or $0.15 per basic and diluted share, compared to net income of $1.1 million or $0.07 per basic and diluted share, reported for the comparable prior year period. When compared to the comparable prior year period, the results for the fourth quarter of fiscal 2012 were negatively impacted by $1.2 million in higher resin costs, $0.8 million relating to a one-time tax valuation allowance against certain state net operating loss carry forwards and $0.4 million in higher costs of products procured from China-based vendors.

Net sales for fiscal 2012 were $437.3 million, an increase of $74.8 million or 21% from the $362.5 million in net sales reported for fiscal 2011. In fiscal 2011 (August 2010), the Company acquired AVID Medical, Inc. (“AVID”); therefore fiscal 2011 reported results included approximately seven months of AVID results. Excluding AVID, Medical Action’s net sales for fiscal 2012 were $298.9 million, representing a comparable increase of $17.8 million or 6% from fiscal 2011. During fiscal 2012, AVID generated net sales of $138.5 million, an increase of approximately 1% over the twelve months ended March 31, 2011 of $137.2 million, of which $81.5 million were included in Medical Action’s fiscal 2011 results.

The increase in net sales, excluding AVID, was comprised of $17.0 million in higher volumes and $0.8 million in higher average selling prices. The increase in volumes was predominantly attributable to higher domestic market penetration in our Patient Care market of $10.5 million and our Clinical Care market of $6.5 million. The increase in average selling prices resulted principally from net price increases of $1.4 million on certain products associated with our Clinical Care market. These were partially offset by a $0.6 decrease in the aggregate average selling price of our Patient Care market. These pricing fluctuations are significantly influenced by competitive pressures, the renewal of certain Group Purchasing Organization supply agreements and a change in the mix of products purchased by our customers.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs